Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nicola Goekbuget
• Treatments: Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Ifosfamide; Methotrexate; Prednisolone; Rituximab; Vincristine; Vindesine

Criteria

Inclusion Criteria:

• Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma

• Age > 15 years

• Written informed consent

Exclusion Criteria:

• Serious secondary diseases, including psychiatric conditions, under which the required therapy compliance is not to be expected

• HIV infection

• Secondary lymphoma following prior chemotherapy/radiotherapy or active second malignancy

• Known severe allergy to foreign proteins

• Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy.

• Pregnancy or nursing

• Participation in other studies that interfere with study therapy